RMD · Q3 2026 Earnings

Margin recovery (FY24) → Margin reset as structural (Q4 FY25) → Margin delivered at midpoint (Q1 FY26) → Margin floor lifted, RCS deferred (Q2 FY26) → Margin upper-half + TAM expansion via M&A (Q3 FY26).

The dominant shift this quarter is the reframing of sleep apnea from a clinical condition into a neurodegenerative-disease-prevention platform — a materially larger TAM framing than anything used in the prior four quarters. Last quarter's emphasis on GLP-1 as a "tailwind, not headwind" has compounded into something more ambitious. Farrell anchored the new framing with: "a meta-analysis published in the journal Geroscience showed that individuals with apnea have a 33% higher risk of developing dementia... This is huge." The signal: management believes the clinical evidence base for sleep apnea is moving from cardiometabolic to neurodegenerative, which is a different addressable-market story and likely the lens through which the next several years of demand-generation spend will be justified.

The GLP-1 narrative has hardened from defensive resolution (Q2: "the headwind thesis is gone") to offensive opportunity (Q3: "GLP-1s are truly a mega trend and a once-in-a-generation demand gen opportunity for ResMed"). Two quarters ago GLP-1 was a tail-risk to neutralize; this quarter it's the largest secular demand-generation tailwind management has ever named. "Once-in-a-generation" is the strongest framing Farrell has used on any external driver in our coverage window.

The fabric-mask story has graduated from product differentiation to quantified clinical moat. Last quarter management discussed mask growth as evidence of resupply firing; this quarter they put a number on the underlying adherence advantage: "the AirTouch N30i drives 6% higher 90-day compliance than its silicone equivalent... Those of you that truly understand the clinical and business relevance of adherence know that those 600 basis points of extra compliance will mean...as this technology expands." This is a different pitch — not "we have a better mask" but "we are changing the basis of competition in the category with quantified clinical economics." It also surfaces a real tension flagged in Q&A: HME profitability on the premium-priced fabric mask is not universal across the ~250-state-payer combinations, and management acknowledged the channel is leaning on direct-to-consumer routes (CBAP.com, EasyBreeze.com) where HME economics don't work. That is the first honest acknowledgment of channel friction on the fabric-mask rollout.

The Noctrix acquisition is the most material strategic move in our coverage window. Last quarter the portfolio was implicitly bounded by sleep apnea, insomnia, and breathing. This quarter the boundary is breached: "RLS is the world's third most prevalent sleep disorder after sleep apnea and insomnia... its revenue growth rate is higher than ResMed's and its gross margin is higher than ResMed's." $340M for ~$24M revenue run-rate is a high multiple (~14x revenue) justified by reimbursement-expansion optionality and the 17M-patient US TAM. Management's framing that Noctrix grows faster and at higher margin than ResMed is the explicit accretion thesis investors will be asked to track.

On RCS, the tonal change is subtle but worth flagging. Q2's language was "return to sustainable high single-digit growth"; this quarter it's "accelerate back to." The word "accelerate" implies momentum building beneath the print rather than a flat plateau. With CC growth at only +4% this quarter, that firmer language carries more burden, not less — and whether it reflects genuine pipeline visibility or rhetorical positioning ahead of FY27 budget season is the central question.